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Abstract The aim this study was to evaluate imaging
Wndings using position emission tomography (PET) in
combination with computed tomography (CT) and 18F-
Xuorodeoxyglucose (18F-FDG) in sinonasal malignant mel-
anoma (SNMM) of the head and neck in a retrospective
analysis of a consecutive cohort of patients. 18F-FDG-PET/
CT examinations were performed for initial staging and
compared with CT or magnetic resonance tomography
(MRI), and 18F-FDG-PET alone. Medical records were
reviewed retrospectively with regard to the location and the
size of the tumor. Furthermore, locoregional and distant
metastases with a consecutive change in therapy detected
by 18F-FDG-PET/CT were assessed. Ten patients suVering
from sinonasal malignant melanoma were staged and fol-
lowed by 18F-FDG-PET/CT imaging. A total of 34 examin-
ations were obtained. 18F-FDG-PET/CT depicted all
primary tumors adequately. Aside from one cerebral metasta-
sis all regional and distant metastases were truly identiWed by
using this method. In summary, if available, 18F-FDG-
PET/CT is a valuable imaging modality for staging and
re-staging sinonasal malignant melanoma to evaluate expan-
sion of the primary tumor, locoregional disease, and distant
metastases.
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Introduction
Mucosal malignant melanoma (MMM) is a very rare tumor
counting for approximately 0.8–1.3% of all melanomas
[1, 2]. The most common region for MMM is the head and
neck, whereas other sites, such as the rectum and the anus,
the urinary system, and the female genitalia may also be
involved [1, 2]. The most prevalent sites of MMM in the
head and neck are the nasal cavity, oral cavity, and the par-
anasal sinuses [1]. Sinonasal malignant melanoma
(SNMM) accounts roughly for 4% of all head and neck
melanomas and sinonasal malignancies alike [3]. Although
the incidence of cutaneous melanoma is increasing, the
incidence of MMM remains stable [1].
Positron emission tomography (PET) with 18F-Xuorode-
oxyglucose (18F-FDG) is increasingly used for initial stag-
ing for head and neck malignancies. It is also an established
tool for initial staging and follow-up imaging of cutaneous
malignant melanomas [4]. In most centers, the standard
imaging technique for MMM in the head and neck at initial
staging is computed tomography (CT) or magnetic reso-
nance imaging (MRI) if there is suspicion for skull base
inWltration. The role of 18F-FDG-PET in the management
of MMM has been validated in a previous report by our
institution [5]. Meanwhile, technology has evolved, and
high-resolution multi-slice CT scanners are integrated in
18F-FDG-PET- systems. The aim of this study was to eluci-
date imaging and the possible additional value of 18F-FDG-
PET/CT on therapeutic management of patients with
MMM, particularly SNMM, when using it at initial staging
or follow-up for locoregional or distant disease.
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We retrospectively reviewed the charts of all patients
treated for MMM of the head and neck at the Department of
Otolaryngology-Head and Neck Surgery, University Hospi-
tal Zurich, Switzerland . We revealed 10 patients, with sin-
onasal involvement only, examined by 18F-FDG-PET/CT
since the introduction of this technique at the Division of
Nuclear Medicine, University Hospital Zurich, Switzer-
land, has been introduced in March 2001. If patients were
referred to our institution with a CT or MRI scan done by
the referring institution, these data were blindly re-evalu-
ated by our double board certiWed radiologist and nuclear
physician. In case of patients without previous imaging, the
CT part from the fused 18F-FDG-PET/CT was evaluated in
a blind way without looking at the 18F-FDG-PET part. All
suspicious lesions detected by physical examination
(endoscopy) and imaging (CT, MRI or 18F-FDG-PET/CT)
were further investigated by histological work- up which
served as the standard of reference. The study was con-
ducted in accordance with the local guidelines established
by the ethics committee for retrospective evaluations. Each
patient was followed by imaging using 18F-FDG-PET/CT
at 6-month intervals.
18F-FDG-PET/CT acquisition
For this study, we used a combined PET/CT system (Discov-
ery STE or Discovery RX, GE Health Systems, Milwaukee,
WI). This device integrates a PET scanner with a multi-slice
helical CT (16 or 64 slices; slice thickness: 2.5 mm) and per-
mits the acquisition of coregistered CT and PET images in
the same session. Patients fasted for at least 4 h prior to scan-
ning, which started approximately 60 min after the injection
of a standard dose of approximately 350 MBq of 18F-FDG.
Patients were examined in the supine position. The CT scan
was acquired during breath holding in the normal expiratory
position. Immediately following the CT acquisition, the PET
emission scan was acquired. The CT data were used for the
attenuation correction and the images were reconstructed
using a standard iterative algorithm (ordered subset expecta-
tion maximization (OSEM)) for 3D PET reconstruction. The
acquired images were postprocessed with a dedicated soft-
ware (AW workstation, GE Health Systems) providing mul-
tiplanar reformatted images of 18F-FDG-PET alone, CT
alone, and fused 18F-FDG-PET/CT with linked cursors.
18F-FDG-PET/CT evaluation
18F-FDG-PET/CT images were retrospectively analyzed by
a double board certiWed radiologist and nuclear physician
with 6 years of experience (K. S.) in reading 18F-FDG-PET/
CT`s of head and neck cancer patients. The 18F-FDG-PET
images were evaluated with regard to the presence and
nature of focal lesions with increased 18F-FDG- uptake.
Attenuation-corrected 18F-FDG-PET images were used for
analysis. Lesions were interpreted as a malignancy if the
uptake was higher than the uptake of the surrounding back-
ground tissue. It was a visual interpretation and not based
on standardized uptake value (SUV) measurements. Fur-
thermore, morphological Wndings of suspicious lesions pro-
vided by the low-dose CT part were also used for
interpretation. 18F-FDG- uptake in muscles, glands, brown
fat or pulmonary inWltration were not interpreted as tumor
or metastases. Four patients were initially examined after
resection and therefore attribution of 18F-FDG-uptake and
histological Wnding was either equivocal or no more uptake
was observed. Two patients received intravenous and oral
contrast agent (Ultravist 300, GastrograWn, Bayer AG Swit-
zerland) for obtaining either a diagnostic CT of the neck or
of the whole body.
Semiquantitative analysis of 18F-FDG-uptake in all sus-
picious lesions was performed by measuring the maximum
standardized uptake value (SUV max).
Results
Clinical and histopathologic Wndings
The charts of ten consecutive patients (4 males, 6 females)
were reviewed. The median age was 65 years (range,
49–82 years). At initial staging, no patient had clinical evi-
dence of a primary melanoma elsewhere in the body. The
MMM involved the nasal cavity and/or the adjacent
ethmoidal and maxillary sinus in all cases (Table 1). Most fre-
quent symptoms at initial presentation were unilateral nasal
hemorrhagic discharge, nasal obstruction, and facial pain.
After clinical investigation including nasal endoscopy, a
CT or MRI scan was acquired. In six patients (patient nos.
1, 3, 4, 5, 6, 7, Table 1), an additional 18F-FDG-PET/CT
scan for initial staging was obtained (Fig. 1a–d). In patient
nos. 2, 8, 9, and 10 an additional 18F-FDG-PET/CT after
initial resection for re-staging was performed.
SNMM was conWrmed histologically and immunohisto-
logically in all patients. Four tumors (nos. 1, 5, 8, 10;
Table 1) showed the histologic pattern of an amelanotic mel-
anoma. The primary tumor was surgically removed in all
patients; postoperative percutaneous radiotherapy (intensity
modulated radiotherapy, IMRT) was given to all but one
patient (patient no. 9, Table 1) with a mean of 58 Gy. Two
patients underwent adjuvant chemotherapy because of distant
metastases detected during follow-up (patient nos. 1, 3;
patient no. 1 was included in a study protocol receiving inter-
feron alpha (IFNa; 3MU s.c., three times a week) plus Dacar-
bazine (DTIC 850 mg/m2 via intravenous (i.v) infusion on123
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was included in a diVerent study (SAKK 50/70) receiving
Bevacizumab (Avastin® 10 mg/kg via i.v. infusion every
2 week) and Temozolomid (Temodal® 150 mg/m2 daily for
7 days every second week)). The median follow- up period
was 17.5 months (range, 8–34 months). Five patients died
as a result of locoregional recurrence and distant metastases
(Table 2). Four Patients are alive with no evidence of dis-
ease, whereas one patient is known to have bone and
pulmonary metastases (Table 2).
18F-FDG-PET/CT Wndings versus other imaging Wndings
18F-FDG-PET/CT was performed at the time of diagnosis
before surgical resection in six patients, within 1 week after
surgery (n = 4), and during follow-up (n = 24). A total of 34
18F-FDG-PET/CT were analyzed for this study.
The follow-up examinations were performed between 5
and 33 months after diagnosis. Increased 18F-FDG-uptake
was observed in all patients with present tumors. All the
18F-FDG-PET/CT Wndings with regard to the detection of
the primary tumor were also detected by CT or MRI-scans
and were well correlated in size. The contrast-enhanced
(ce) CT part of the 18F-FDG-PET/CT was able to approve
the 18F-FDG-PET Wndings. One cerebral metastasis was not
detected either by 18F-FDG-PET or by ceCT scanning and
could only be found on MRI. Three suspicious lesions
revealed by native CT (one osteolytic lesion in the spine;
one small lesion in the lung; one enlarged lymph node in
the mediastinum) showed none, or very little 18F-FDG
activity. During follow-up, these lesions turned out to be
false-positive lesions as no growth or onset of symptoms
could be shown.
Increased activity in soft tissue was located in brown fat
tissue in one patient. Patient no. 10 showed repeatedly local
18F-FDG activity at the site of resection (SUV 4.4-4.7). The
fused CT did not approve a growing mass at this position
and malignancy was Wnally ruled out by biopsy.
Fig. 1 56-year-old female suVering from a sinonasal malignant mela-
noma originating from the right nasal cavity involving the ethmoid si-
nus, the dura, and the periorbit. a T1 weighted MRI with Gadolinium,
axial section. b Bone window CT with contrast agent, axial section.
c Fused 18F-FDG-PET-CT, axial section. d 18F-FDG-PET, axial
section123
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In general
Primary mucosal malignant melanoma (MMM) is a rare
disease and occurs in older patients of both genders. Inci-
dence of nasal cavity MMM was reported to be 0.018/10
[5] per year [6]. Only around 4% of all head and neck mela-
nomas arise in the nasal cavity or adjacent paranasal
sinuses [3]. The most common site of origin is the nasal
septum, closely followed by the lateral nasal wall and the
middle and inferior turbinates [3, 7]. Lymph node metasta-
ses are generally noted in about one-third of mucous mem-
brane head and neck melanomas at initial presentation,
implying a worse prognosis [1, 8]. The poorer prognosis for
mucous membrane melanoma has been related to the tumor
bulk (size), delay in diagnosis resulting from the non-spe-
ciWc nature of the presenting symptoms, diYcult visual
examination, and technical inaccessibility of the primary
tumor [9].
Sinonasal malignant melanomas have, like cutaneous
malignant melanomas, an increased glucose metabolism.
The role of 18F-FDG-PET in staging mucosal malignant
melanomas of the head and neck has already been aYrmed
[5]. 18F-FDG-PET imaging is also known to be more sensi-
tive and speciWc than CT for the detection of metastasis in
melanoma patients [10].
Advantages of 18F-FDG-PET/CT
At initial staging, all our patients showed increased 18F-FDG
uptake at the tumor site and could thus be easily identiWed.
18F-FDG-PET-only imaging is lacking anatomical infor-
mation. Complementary anatomical imaging is often
required, especially for surgical therapy planning in this
complex anatomical area. Coregistred 18F-FDG-PET/CT
has been available for a few years and provides such
anatometabolic datasets in a single examination. 18F-FDG-
PET/CT has been found to be superior to CT alone and
PET alone in staging and evaluation of therapy response
in several oncological diseases including malignant mela-
noma [11–13].
18F-FDG-PET/CT as a functional and anatomical
imaging method provides additional information for sur-
gical therapy planning. Especially in the nasal cavity and
paranasal sinuses, where anatomy is diYcult and diVer-
ent vital structures are in close proximity, 18F-FDG-PET/
CT appears to be superior to 18F-FDG-PET alone. Partic-
ularly in recurrent tumors it seems essential to distin-
guish scar-tissue from melanoma masses and predicts the
extent of aVection, which is not possible by CT alone.
18F-FDG-PET without the additional information of the
fused CT on the other hand is not able to give enough
spatial resolution to perform exact surgical planning in
the setting of the pre-operated nasal cavities and parana-
sal sinuses, where CT data add valuable information on
fused images.
In a previous study by Department of Otolaryngology-
Head and Neck Surgery, University Hospital Zurich,
Switzerland, it could be shown that local tumor control in
SNMM can be achieved in many cases and the majority of
patients die from distant metastasis [7]. Hence, 18F-FDG-
PET/CT is in our opinion the imaging of choice during the
follow-up period.
Table 1 Patient and tumor characteristics
f Female, m Male, NMC non-melanotic melanoma, MC melanotic melanoma, MRI magnetic resonance imaging, CT computed tomography, SUV
standardized uptake value, RT radiotherapy, C chemotherapy
Sizes indicated in anterio-posterior £ cranio-caudal £ right-left distances (in cm)
a After resection
No Sex Age Localization Histology SUV max 
initial
Activity size 
in PET/CT
Preoperative 
size in MRI or CT
Therapy Current status
1 m 52 Nasal cavity 
Ethmoidal sinus
NMC 7.1 0.76 £ 0.65 £ 0.9 n/a Surgery RT & C Dead of disease
2 f 51 Septum MC n/aa n/aa n/a Surgery RT Alive no disease
3 m 67 Maxillary sinus MC 3.4 4.2 £ 4.7 £ .4.8 4.5 £ 5.1 £ 4.75 Surgery RT & C Dead of disease
4 m 78 Nasal cavity MC 10.8 3.7 £ 3.8 £ 3.2 4.8 £ 5.4 £ 2.5 Surgery RT Dead of disease
5 f 82 Nasal cavity NMC 4.2 1.7 £ 1.6 £ 0.9 3.1 £ 3.2 £ 1.3 Surgery RT Alive with disease
6 f 49 Ethmoidal sinus MC 11.5 3.2 £ 3.4 £ 3.5 3.4 £ 3.3 £ 2.8 Surgery RT Dead of disease
7 f 56 Nasal cavity MC 6.4 3.1 £ 3.7 £ 2.4 3.8 £ 4.2 £ 3.0 Surgery RT Alive no disease
8 f 67 Middle turbinate NMC n/aa n/aa n/a Surgery RT Dead of disease
9 F 63 Inferior turbinate MC n/aa n/aa n/a Surgery Alive no disease
10 m 81 Spheno-ethmoidal NMC 4.9a 1.4 £ 2.2 £ 2.0a n/a Surgery RT Alive no disease123
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A known limitation of 18F-FDG-PET imaging is the identi-
Wcation of brain metastases due to the high background
metabolism as well as small melanoma metastases, where
the spatial resolution of 18F-FDG-PET/CT- imaging is not
small enough [14]. We, too, did encounter these diYculties,
as one cerebral metastasis was not seen during follow-up
18F-FDG-PET/CT scans and was only identiWed by MRI.
Fused 18F-FDG-PET/MRI might possibly eliminate this
problem in the future.
In a study by Gulec et al. [14] all of the 29 lesions larger
than 1 cm showed 18F-FDG uptake, whereas only two out of
15 lesions smaller than 1 cm were detected by 18F-FDG-PET
alone14. A theoretical three-dimensional spatial resolution of
4 mm can be achieved by modern 18F-FDG-PET/CT scanners.
However, due to motion and the tumor related uptake ratio, a
spatial resolution of 6-8 mm can be expected realistically [15].
Table 2 Clinical and radiological information for every patient given at time of 18F-FDG-PET/CT examinations
R0 resection with neither macroscopic nor microscopic evidence of residual tumor, SUV max maximum standardized uptake value, n/a: no focal
uptake
a False-positive uptake
Patient 
number
18F-FDG-PET/CT 
examinations
SUV max of 
the primary tumor
Locoregional 
recurrence
R0 resection at 
Wrst intervention
All detected 
metastases
1 Initial staging 7.1 No None
1st follow-up 2.8 Yes Neck
2nd follow-up 6.3 Yes Neck, bone
3rd follow-up 4.5 Yes Neck, bone, liver
4th follow-up n/a No Neck, bone, kidney
2 Initial staging n/a Yes None
1st follow-up n/a No None
2nd follow-up n/a No None
3rd follow-up n/a No None
4th follow-up n/a No None
3 Initial staging 3.4 Yes None
1st follow-up 3.7 Yes Adrenal gland
2nd follow-up 4.7 Yes Adrenal gland
4 Initial staging 10.8 Yes None
1st follow-up n/a No Lungs
5 Initial staging 4.2 No None
1st follow-up 12.0 Yes Lungs, bone
6 Initial staging 11.5 Yes None
1st follow-up 4.8 Yes Lungs, brain (MRI)
7 Initial staging 4.8 No None
1st follow-up n/a No None
2nd follow-up n/a No None
3rd follow-up 2.8a No None
4th follow-up 2.3a No None
5th follow-up n/a No None
8 Initial staging n/a Yes No Lungs, bone
9 Initial staging n/a Yes None
1st follow-up n/a No None
2nd follow-up n/a No None
10 Initial staging 4.9 Yes None
1st follow-up n/a No None
2nd follow-up 4.4a No None
3rd follow-up 3.8a No None
4th follow-up 4.7a No None123
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show low sensitivities at initial staging of patients suVering
from malignant cutaneous melanomas and therefore meta-
bolic imaging should only be recommended as a Wrst-line
diagnostic tool for selected melanoma patients in high-risk
groups. Although none of our patients was found to have
regional or distant metastasis upon Wrst imaging workup, all
of the primary sites could be identiWed adequately. This is
also due to late presentation of the oligosymptomatic patient
in a late stadium with large tumor size, as stated above. As a
rule, we believe it is advantageous performing the same fol-
low-up imaging modality as that used for primary workup.
The cost-eVectiveness of 18F-FDG-PET/CT
DiVerent authors have described the cost-eVectiveness of
18F-FDG PET/CT in staging head and neck squamous cell
carcinoma (HNSCC) [17, 18]. The drawback of staging
patients with 18F-FDG PET/CT is the relatively high num-
ber of false-positive Wndings. Although many of the posi-
tive 18F-FDG PET/CT Wndings will have an impact on the
patient treatment, the costs of subsequent investigations and
the burden caused to patients by additional investigations
are considerable. Therefore, the indication for metabolic
imaging should be handled reluctantly. A recent study
showed 18F-FDG PET/CT is the most eVective pretreat-
ment screening method for distant metastases in HNSCC
patients with risk factors [19]. It is our opinion, that in
future, when integrated 18F-FDG PET/CT and MRI scan-
ners become routine, this will be the most cost-eVective
imaging method for SNMM.
The role of CT
Three 18F-FDG- negative lesions (spine, lung, and medi-
astinum) detected and found to be suspicious by native
CT were shown to be unsuspicious on 18F-FDG-PET
scanning. All of these Wndings were proven not to be
malignant upon follow-up examination. These lesions
represent false-positive Wndings on native CT scans;
therefore, CT scanning should be ultimately performed
ce, and, furthermore, 18F-FDG negativity shows the
potential to identify unreliable CT Wndings. On the other
hand it can be challenging, especially in the head and
neck area, to distinguish physiological or inXammatory
uptake from malignant tissue which can be downsized by
the ceCT part [20].
As malignant mucosal melanoma is a very rare condi-
tion, it is diYcult to show signiWcant improvements in stag-
ing with 18F-FDG-PET/CT because of the small number of
patients. However, we know from previous reports on 18F-
FDG-PET/CT imaging that only few false-negative results
are obtained, leading to a high negative predictive value,
which is also supported by the current study. As modern
18F-FDG-PET/CT scanners are providing a better resolu-
tion of the added CT information, one can also expect less
false-positive Wndings. As shown, it is important to perform
a ceCT part, which is not routine in many centers.
The role of MRI
To evaluate dural or intracranial involvement, MRI seems
to be indisputably the imaging modality of choice. How-
ever, the tumor’s appearance is dependent on the amount of
melanin found within. Melanotic tumors usually show
hyperintensity on T1 images, whereas hypomelanotic or
amelanotic melanomas may appear intermediate in signal
intensities [21–23]. In our series 4/10 SNMM were amela-
notic. In previous studies of mucosal melanoma, the fre-
quency of amelanotic melanoma ranged from 25 to 42.9%
[22]. All of the tumors in our series had increased 18F-FDG
uptake independent of their melanin contents which is in
accordance with the literature.
Conclusion
In addition to the previously published experience con-
cerning 18F-FDG-PET imaging for the detection of
MMM, the updated data presented in this study suggest
that 18F-FDG-PET/CT is superior to other imaging, e.g.,
CT or MRI scans, with its known limitations. Owing to
the combined 18F-FDG-PET and CT part, the visibility
of SNMM is not solely dependent on 18F-FDG activity
anymore.
Therefore, if available, contrast-enhanced 18F-FDG-
PET/CT, in our opinion, is the adequate staging and re-
staging imaging modality to respond to the question of the
expansion of the primary tumor, locoregional disease, or
distant metastases.
If dural or intracranial involvement is clinically suspected,
we believe that, additional MRI is required. However, it
will never replace 18F-FDG-PET/CT scanning as a staging
modality unless MRI is fused with 18F-FDG-PET.
ConXict of interest None.
References
1. Chang A, Karnell L, Menck H (1998) The National Cancer Data
Base report on cutaneous and noncutaneous melanoma: a
summary of 84, 836 cases from the past decade. The American
College of Surgeons Commission on Cancer and the American
Cancer Society. Cancer 83:1664–1678
2. Andersen L, Berthelsen A, Hansen H (1992) Malignant melanoma
of the upper respiratory tract and the oral cavity. J Otolaryngol
21:180–185123
Eur Arch Otorhinolaryngol (2012) 269:127–133 1333. Thompson L, Wieneke J, Miettinen M (2003) Sinonasal tract and
nasopharyngeal melanomas: a clinicopathologic study of 115 cases
with a proposed staging system. Am J Surg Pathol 27:594–611
4. Steinert H, Huch Böni R, Buck A et al (1995) Malignant mela-
noma: staging with whole-body positron emission tomography
and 2-[F-18]-Xuoro-2-deoxy-D-glucose. Radiology 195:705–709
5. Goerres G, Stoeckli S, von Schulthess G, Steinert H (2002) FDG
PET for mucosal malignant melanoma of the head and neck.
Laryngoscope 112:381–385
6. Chiu N, Weinstock M (1996) Melanoma of oronasal mucosa.
Population-based analysis of occurrence and mortality. Arch
Otolaryngol Head Neck Surg 122:985–988
7. Roth TN, Gengler C, Huber GF, Holzmann D (2010) Outcome of
sinonasal melanoma: clinical experience and review of the litera-
ture. Head Neck 32(10):1385–1392
8. Lengyel E, Gilde K, Remenár E, Esik O (2003) Malignant mucosal
melanoma of the head and neck. Pathol Oncol Res 9:7–12
9. Brandwein M, Rothstein A, Lawson W, Bodian C, Urken M
(1997) Sinonasal melanoma. A clinicopathologic study of 25 cases
and literature meta-analysis. Arch Otolaryngol Head Neck Surg
123:290–296
10. Swetter S, Carroll L, Johnson D, Segall G (2002) Positron emis-
sion tomography is superior to computed tomography for meta-
static detection in melanoma patients. Ann Surg Oncol 9:646–653
11. Strobel K, Dummer R, Husarik D, Pérez Lago M, Hany T, Steinert
H (2007) High-risk melanoma: accuracy of FDG PET/CT with
added CT morphologic information for detection of metastases.
Radiology 244:566–574
12. Strobel K, Skalsky J, Steinert H et al (2007) S-100B and FDG-
PET/CT in therapy response assessment of melanoma patients.
Dermatology 215:192–201
13. Reinhardt M, Joe A, Jaeger U et al (2006) Diagnostic performance
of whole body dual modality 18F-FDG PET/CT imaging for N- and
M-staging of malignant melanoma: experience with 250 consecu-
tive patients. J Clin Oncol 24:1178–1187
14. Gulec S, Faries M, Lee C et al (2003) The role of Xuorine-18
deoxyglucose positron emission tomography in the management
of patients with metastatic melanoma: impact on surgical decision
making. Clin Nucl Med 28:961–965
15. Von Schulthess G, Hany T (2008) Imaging and PET–PET/CT
imaging. J Radiol 89:438–447 (quiz 48)
16. Veit-Haibach P, Vogt F, Jablonka R et al (2009) Diagnostic accu-
racy of contrast-enhanced FDG-PET/CT in primary staging of
cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging
36:910–918
17. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK
(1996) Cost-eVectiveness of PET imaging in clinical oncology.
Nucl Med Biol 23:737–743
18. Hollenbeak CS, Lowe VJ, Stack BC Jr (2001) The cost-eVective-
ness of Xuorodeoxyglucose 18-F positron emission tomography in
the N0 neck. Cancer 92:2341–2348
19. Uyl-de Groot CA, Senft A, de Bree R, Leemans CR, Hoekstra OS
(2010) Chest CT and whole-body 18F-FDG PET are cost-eVective
in screening for distant metastases in head and neck cancer pa-
tients. J Nucl Med 51:176–182
20. Goerres G, Von Schulthess G, Hany T (2002) Positron emission
tomography and PET CT of the head and neck: FDG uptake in nor-
mal anatomy, in benign lesions, and in changes resulting from
treatment. AJR Am J Roentgenol 179:1337–1343
21. Yousem D, Li C, Montone K et al (1996) Primary malignant mel-
anoma of the sinonasal cavity: MR imaging evaluation. Radio-
graphics 16:1101–1110
22. Yoshioka H, Kamada T, Kandatsu S et al (1998) MRI of mucosal
malignant melanoma of the head and neck. J Comput Assist To-
mogr 22:492–497
23. Uchiyama Y, Murakami S, Kawai T, Ishida T, Fuchihata H (1998)
Primary malignant melanoma in the oral mucosal membrane with
metastasis in the cervical lymph node: MR appearance. AJNR Am
J Neuroradiol 19:954–955123
